Cathie Wood's Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update from studies Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
⏲ Duration: 1:1 👁 View: 3.3M times ✓ Published: 06-May-2024
Description: Following Friday's purchase, this biopharma's weighting in ARKG stood at 1.06%, attributed to the 51,712 shares held by the exchange-traded fund.<br/>The biopharma company has opted to prioritize a pipeline asset that is in Phase 2 study for obesity and is positive about its potential.